Solid Dose Formulation Troubleshooter
Diagnose solid dose formulation failures and optimize excipient strategies
What You Can Do
You can rapidly diagnose why your solid dose formulations are failing—whether due to poor flowability, insufficient hardness, moisture sensitivity, dissolution issues, or API degradation. The skill walks you through structured root-cause analysis, maps chemical interactions between your drug substance and excipients across pH, temperature, and moisture conditions, then prioritizes excipient replacements based on regulatory precedent and manufacturing feasibility. You'll document all decisions with clear rationale ready for CMC submissions.
Features
Evaluate drug-excipient interactions across storage conditions, pH ranges, and moisture levels to predict degradation pathways and incompatibilities
Systematically identify whether issues stem from flowability, compressibility, moisture uptake, dissolution kinetics, or API stability
Receive prioritized replacement candidates based on pharmaceutical precedent, regulatory acceptance, and manufacturing feasibility
Assess segregation, blending uniformity, compression challenges, and process robustness before pilot batches
Generate justified excipient selections and test rationales ready for regulatory submissions and change controls
Anticipate moisture uptake, API degradation, and long-term shelf-life risks for proposed formulation changes
Evaluate compatibility impacts when switching excipient sources or grades to inform risk assessments
Example Output
Example 1: Moisture Sensitivity Issue
Input: Tablet hardness dropping after 3 months at 25°C/60% RH; API is hygroscopic
Output:
- Root Cause: Microcrystalline cellulose (Avicel PH101) absorbing moisture, softening tablet matrix
- Recommended Swaps: Low-substitution hypromellose (HPMC) or pregelatinized starch; reduce MCC to 15–20%
- Testing Priority: DVS (dynamic vapor sorption) on reformulated blend; accelerated 25°C/75% RH for 3 months
- CMC Rationale: HPMC precedent in 500+ approved tablets; lower moisture equilibrium at shelf conditions
Example 2: Poor Flowability in High-Speed Tableting
Input: Weight variation exceeding ±7.5%; die filling inconsistent at 100 tablets/min
Output:
- Root Cause: Magnesium stearate (1% w/w) over-lubricated, reducing particle friction; API needle crystals jamming hopper
- Optimization Steps: Reduce lubricant to 0.5%, add colloidal silicon dioxide (2%) for flow aid; consider spheronized API or wet-milled batch
- Manufacturing Controls: Angle of repose <35°, Hausner ratio <1.25; validate at target speed
- Stability Impact: No expected change; confirm dissolution remains >85% at 30 min
Example 3: Excipient Supplier Qualification
Input: Primary supplier of croscarmellose sodium unavailable; need to qualify alternative grade
Output:
- Compatibility Check: Cross-reactivity screening vs. current binder/disintegrant blend; moisture content specification alignment
- Risk Assessment: Medium risk if substitution grade has different particle size; low risk if spec-equivalent
- Validation Plan: 3-tablet dissolution profiles, hardness, friability, and 1-month stability at accelerated conditions
- Regulatory Path: Document as supplier change via Type C variation or annual report depending on jurisdiction
What's Included
- SKILL.md: Complete skill instruction file with structured decision workflows
- Excipient Compatibility Assessment Template: Systematic checklist for drug-excipient interaction evaluation across pH, temperature, and moisture
- Formulation Failure Diagnosis Flowchart: Decision tree to isolate root causes (flowability, hardness, dissolution, stability)
- Excipient Replacement Priority Matrix: Framework to rank candidate excipients by regulatory precedent, cost, and manufacturability
- CMC Documentation Checklist: Rationale templates for regulatory submissions justifying excipient selections and change controls
Who It's For
- Formulation Scientists — optimizing solid dose designs during mid-to-late-stage development and troubleshooting batch failures
- Process Engineers — assessing manufacturability impacts of formulation changes and predicting scale-up risks
- Quality Assurance & CMC Specialists — documenting excipient justifications and change controls for regulatory submissions
- Regulatory Affairs Teams — building evidence packages for supplier changes, excipient substitutions, and manufacturing variations
- Contract Manufacturers — rapidly qualifying alternative formulations when excipient availability or cost pressures emerge
Best For
- Diagnosing why tablets/capsules are failing in-process or stability testing
- Evaluating excipient swaps due to supplier changes, cost reduction, or availability constraints
- Optimizing formulations for manufacturability (flowability, compressibility, blending uniformity)
- Building CMC sections with justified excipient selections and compatibility data
- Predicting moisture sensitivity, dissolution, and API degradation risks before scale-up
You might also like
You can design and execute bioanalytical method validations aligned with FDA Guidance for Industry and ICH guidelines, interpret complex validation data against regulatory acceptance criteria, and systematically troubleshoot analytical failures to identify root causes and corrective actions. This skill accelerates validation timelines by 20–30%, minimizes regulatory rework, and provides structured decision trees for problems that typically require expert consultation.
by kody-wClaude reviews your injection mold, stamping die, or precision tool designs for manufacturability, cost reduction opportunities, and tolerance optimization. You provide CAD specifications, material details, and production volume—Claude identifies specific design modifications, material alternatives, and tolerance adjustments that reduce tooling complexity and unit costs without compromising performance.
by kody-w
This skill evaluates your current workstation setup, identifies ergonomic risks, and delivers actionable recommendations to reduce strain and injury. It analyzes factors like monitor height, desk ergonomics, seating, keyboard positioning, and lighting to create a personalized improvement plan that you can implement immediately.
by kody-w
Systematically evaluate ingredient compatibility against your active pharmaceutical ingredients, predict formulation behavior and stability risks, and troubleshoot phase separation, incompatibility, and irritation issues in real time. Generate ICH-aligned stability protocols, excipient safety summaries, and regulatory-ready documentation that accelerates IND, NDA, and ANDA submissions without replacing lab validation.
by kody-w
Analyze your PLC code and ladder logic to identify logic errors, safety violations, and inefficiencies before they reach production. You'll get detailed diagnostics of control system failures, safety compliance verification against IEC 61131 standards, and optimization recommendations for automation sequences. This skill helps you prevent costly downtime, ensure worker safety, and improve system performance across manufacturing operations.
by kody-w
You can systematically identify production bottlenecks, forecast capacity constraints before they impact delivery, and optimize resource utilization across your manufacturing operations. By analyzing historical production data, demand forecasts, and resource availability, you'll generate actionable insights to maximize throughput and reduce downtime.
by kody-w
You systematically analyze workstations and work tasks for ergonomic hazards using industry-standard assessment methods (RULA, NIOSH, ISO 11228). You receive quantified risk scores, pinpointed hazard identification, and prioritized mitigation recommendations ranked by impact and feasibility. You can generate compliance-ready documentation and implement targeted interventions to reduce musculoskeletal injury risk.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-w